摘要

【摘要】
目的：分析抗抑郁治疗对晚期非小细胞肺癌（nonsmall-cell lung cancer, NSCLC）患者抑郁状态的改善效果及患者T细胞亚群及NK细胞变化情况。

方法：将2015年8月至2018年9月期间因晚期NSCLC于我院进行治疗的87例患者作为研究对象，采用随机数字表法将所有患者分为观察组与对照组。对照组仅予以常规化疗，观察组在对照组基础上加用抗抑郁治疗。对比两组不同治疗模式下抑郁状态的改善情况，分析两组T细胞亚群及NK细胞变化情况。

结果：观察组抑郁症状缓解效果显著高于对照组（P<0.05）；观察组经治疗后T细胞亚群中CD3+、CD4+、CD8+水平均显著高于对照组，CD4+/CD8+显著低于对照组（P<0.05）；观察组NK细胞水平升高程度较对照组更加显著（P<0.05）。

结论：针对NSCLC患者进行常规化疗过程中，以氟西汀进行抗抑郁辅助治疗除对患者抑郁症状有显著改善外，还能提高机体免疫能力，有临床推广应用价值。

关键词：【关键词】抗抑郁治疗；晚期；非小细胞肺癌；T细胞亚群；NK细胞

ABSTRACT

【Abstract】
Objective: To analyze the effect of antidepressant therapy on the depression status of patients with advanced non-small cell lung cancer (NSCLC) and the changes of T cell subsets and NK cells.

Methods: 87 patients with advanced NSCLC who were treated in our hospital from August 2015 to September 2018 were divided into observation group and control group by random number table method. The control group received conventional chemotherapy only, while the observation group was given antidepressant treatment on the basis of the control group. The improvement of depressive state was compared between the two groups under different treatment modes, and the changes of T cell subsets and NK cells in the two groups were analyzed. Result: The relief effect of depression in the observation group was significantly higher than that in the control group (P<0.05). The relief rate of depression in the observation group was significantly higher than that of the control group (P< 0.05); in the observation group, the levels of CD3+, CD4+, and CD8+ in the T cell subsets were significantly higher than those in the control group, and CD4+/CD8+ was significantly lower than that in the control group (P<0.05). The group was more significant (P < 0.05).

Conclusion  : In the course of routine chemotherapy for patients with NSCLC, anti-depression adjuvant therapy with fluoxetine can significantly improve the body's immune ability, and it can also improve the body's immunity.

Key words: [Key words] antidepressant therapy; advanced; non-small cell lung cancer; T cell subsets; NK cells